Because of these potentially oncogenic properties, KLF5 activity has been widely investigated and found to be dysregulated in cancers of the pancreas, stomach, breast, prostate and esophageal squamous cell carcinoma; in particular, upregulated KLF5 activity has been extensively studied in colorectal cancer [33], [34], [35], [36], [37], [38]. This evidence concerns the gene KLF5 and pancreatic neoplasm.